Skip to search formSkip to main contentSkip to account menu

response to carboplatin

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
519Background: HRD status is significantly associated with a higher rate of response to neoadjuvant platinum-based therapy and… 
2017
2017
Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers
Background:The biological mechanisms underlying early- and advanced-stage epithelial ovarian cancers (EOCs) are still poorly… 
2016
2016
Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast.
Malignantmyoepitheliomaof thebreast (MMB) is extremely rare and often presents as a diagnostic challenge. Myoepithelial cells are… 
2011
2011
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
2006
2006
A novel role for placental leucine aminopeptidase (P‐LAP) as a determinant of chemoresistance in endometrial carcinoma cells
In several recent studies, we have shown that P‐LAP can be a poor prognostic factor and a factor of chemoresistance in… 
2004
2004
Time response of carboplatin-induced nephrotoxicity in rats.
2002
2002
Dose response of carboplatin-induced nephrotoxicity in rats.
Abstract: Carboplatin, a second-generation platinum-containing anticancer drug, is currently being used against a variety of… 
1995
1995
Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
The clinical presentation of prostate-hormone refractory tumours in 90% of patients is characterised by sclerotic bone metastasis… 
Review
1995
Review
1995
Ovarian cancer, from the laboratory to the clinic: challenges for the future.
Over the past 20 years ovarian cancer has provided a vivid illustration of the successes, failures and challenges for the medical… 
1991
1991
Phase II study of carboplatin in advanced breast cancer: preliminary results.
The antitumor activity of carboplatin (400 mg/m2 intravenously every 4 weeks) in advanced breast cancer was evaluated in two… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)